Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Receives Average Recommendation of “Moderate Buy” from Analysts

Shares of Karyopharm Therapeutics Inc. (NASDAQ:KPTI) have earned a consensus rating of “Moderate Buy” from the seven ratings firms that are presently covering the company, MarketBeat reports. One investment analyst has rated the stock with a sell rating and six have given a buy rating to the company. The average twelve-month price target among brokers that have updated their coverage on the stock in the last year is $14.8333.

Several brokerages have issued reports on KPTI. Piper Sandler restated an “overweight” rating and issued a $12.00 target price on shares of Karyopharm Therapeutics in a research note on Wednesday, December 17th. Cantor Fitzgerald assumed coverage on Karyopharm Therapeutics in a report on Thursday, February 5th. They issued an “overweight” rating for the company. Weiss Ratings restated a “sell (d-)” rating on shares of Karyopharm Therapeutics in a research note on Monday, December 29th. HC Wainwright reaffirmed a “buy” rating and set a $15.00 price objective on shares of Karyopharm Therapeutics in a report on Wednesday, February 18th. Finally, The Goldman Sachs Group set a $12.00 target price on shares of Karyopharm Therapeutics in a research report on Wednesday, December 17th.

Karyopharm Therapeutics Stock Down 0.6%

Shares of KPTI stock opened at $8.77 on Monday. The firm has a market cap of $160.84 million, a P/E ratio of -0.53 and a beta of 0.13. The company has a 50 day moving average of $7.76 and a 200-day moving average of $6.77. Karyopharm Therapeutics has a 12-month low of $3.51 and a 12-month high of $10.99.

Karyopharm Therapeutics (NASDAQ:KPTI) last posted its quarterly earnings data on Friday, February 13th. The company reported ($2.23) EPS for the quarter, beating the consensus estimate of ($2.26) by $0.03. The firm had revenue of $34.08 million during the quarter, compared to analysts’ expectations of $33.16 million. As a group, equities analysts expect that Karyopharm Therapeutics will post -0.71 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the business. Baird Financial Group Inc. purchased a new position in shares of Karyopharm Therapeutics during the 2nd quarter valued at $45,000. XTX Topco Ltd purchased a new stake in shares of Karyopharm Therapeutics in the second quarter worth $56,000. Corient Private Wealth LLC bought a new stake in Karyopharm Therapeutics during the fourth quarter valued at $74,000. Tudor Investment Corp ET AL purchased a new position in Karyopharm Therapeutics during the fourth quarter worth about $95,000. Finally, Persistent Asset Partners Ltd purchased a new position in Karyopharm Therapeutics during the fourth quarter worth about $135,000. 66.44% of the stock is owned by institutional investors.

About Karyopharm Therapeutics

Karyopharm Therapeutics (NASDAQ: KPTI) is a clinical-stage biopharmaceutical company focused on discovering and developing novel first-in-class drugs that target the nuclear export protein XPO1. The company’s lead product, selinexor (marketed as XPOVIO), is an oral selective inhibitor of nuclear export (SINE) compound approved for treatment of multiple myeloma and diffuse large B-cell lymphoma. In addition to selinexor, Karyopharm’s pipeline includes second-generation SINE compounds and combination studies in solid tumors and hematologic malignancies.

Founded in 2008 and headquartered in Newton, Massachusetts, Karyopharm has built a research platform around modulation of nuclear export pathways.